Bin Wan Mohd Nor W, Kwong S, Fuzi A, Said N, Jamil A, Lee Y
Int J Mol Med. 2025; 55(3).
PMID: 39820715
PMC: 11759585.
DOI: 10.3892/ijmm.2025.5487.
Rahdan F, Saberi A, Saraygord-Afshari N, Hadizadeh M, Fayeghi T, Ghanbari E
Heliyon. 2024; 10(20):e39489.
PMID: 39498055
PMC: 11532857.
DOI: 10.1016/j.heliyon.2024.e39489.
Shafi S, Ahmed Khan M, Ahmad J, Rabbani S, Singh S, Najmi A
Curr Drug Targets. 2024; 26(2):109-131.
PMID: 39377414
DOI: 10.2174/0113894501335877240926101134.
Ni X, Lu C, Xu G, Ma J
Acta Pharmacol Sin. 2024; 45(8):1533-1555.
PMID: 38622288
PMC: 11272797.
DOI: 10.1038/s41401-024-01264-1.
Hu B, Zhang X, Zhu S, Wang C, Deng Z, Wang T
Eur J Med Res. 2024; 29(1):92.
PMID: 38297388
PMC: 10829481.
DOI: 10.1186/s40001-024-01672-3.
The YTHDC1/GLUT3/RNF183 axis forms a positive feedback loop that modulates glucose metabolism and bladder cancer progression.
Yan B, Li X, Peng M, Zuo Y, Wang Y, Liu P
Exp Mol Med. 2023; 55(6):1145-1158.
PMID: 37258572
PMC: 10318083.
DOI: 10.1038/s12276-023-00997-z.
Functional importance of glucose transporters and chromatin epigenetic factors in Glioblastoma Multiforme (GBM): possible therapeutics.
Chamarthy S, Mekala J
Metab Brain Dis. 2023; 38(5):1441-1469.
PMID: 37093461
DOI: 10.1007/s11011-023-01207-5.
Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients.
Ma L, Chen H, Yang W, Ji Z
Int J Mol Sci. 2023; 24(5).
PMID: 36902193
PMC: 10003512.
DOI: 10.3390/ijms24054760.
An appraisal of the current status of inhibition of glucose transporters as an emerging antineoplastic approach: Promising potential of new pan-GLUT inhibitors.
Temre M, Kumar A, Singh S
Front Pharmacol. 2022; 13:1035510.
PMID: 36386187
PMC: 9663470.
DOI: 10.3389/fphar.2022.1035510.
Epigenetic Small-Molecule Modulators Targeting Metabolic Pathways in Cancer.
Das D, Karthik N, Taneja R
Subcell Biochem. 2022; 100:523-555.
PMID: 36301505
DOI: 10.1007/978-3-031-07634-3_16.
MicroRNAs-mediated regulation of glucose transporter (GLUT) expression in glioblastoma.
Beylerli O, Sufianova G, Shumadalova A, Zhang D, Gareev I
Noncoding RNA Res. 2022; 7(4):205-211.
PMID: 36157351
PMC: 9467858.
DOI: 10.1016/j.ncrna.2022.09.001.
Prognostic value of the ferroptosis-related gene in gastric cancer and related immune mechanisms.
Lin L, Que R, Wang J, Zhu Y, Liu X, Xu R
Front Genet. 2022; 13:919313.
PMID: 35957685
PMC: 9358142.
DOI: 10.3389/fgene.2022.919313.
miR-1307-5p suppresses proliferation and tumorigenesis of bladder cancer via targeting MDM4 and the Hippo signaling pathway.
Huang W, Zhang C, Xiong S, Zhou X, Wang G, Guo J
Discov Oncol. 2022; 13(1):57.
PMID: 35778656
PMC: 9249964.
DOI: 10.1007/s12672-022-00512-2.
MicroRNAs in the Regulation of Solute Carrier Proteins Behind Xenobiotic and Nutrient Transport in Cells.
Yi C, Yu A
Front Mol Biosci. 2022; 9:893846.
PMID: 35755805
PMC: 9220936.
DOI: 10.3389/fmolb.2022.893846.
Current Development and Application of Anaerobic Glycolytic Enzymes in Urothelial Cancer.
Yang Y, Chuang H, Kuo W, Lin B, Chang Y
Int J Mol Sci. 2021; 22(19).
PMID: 34638949
PMC: 8508954.
DOI: 10.3390/ijms221910612.
Glucose Transporters as a Target for Anticancer Therapy.
Pliszka M, Szablewski L
Cancers (Basel). 2021; 13(16).
PMID: 34439338
PMC: 8394807.
DOI: 10.3390/cancers13164184.
Functional miR-142a-3p Induces Apoptosis and Macrophage Polarization by Targeting and in Grass Carp ().
Tao L, Pang Y, Wang A, Li L, Shen Y, Xu X
Front Immunol. 2021; 12:633324.
PMID: 34262558
PMC: 8273434.
DOI: 10.3389/fimmu.2021.633324.
Regulatory Mechanisms of LncRNAs in Cancer Glycolysis: Facts and Perspectives.
Huang P, Zhu S, Liang X, Zhang Q, Luo X, Liu C
Cancer Manag Res. 2021; 13:5317-5336.
PMID: 34262341
PMC: 8275123.
DOI: 10.2147/CMAR.S314502.
A Comprehensive Analysis of the Downregulation of and Its Prognostic Significance by Targeting and in Ovarian Cancer.
Feng P, Ge Z, Guo Z, Lin L, Yu Q
Front Mol Biosci. 2021; 8:687576.
PMID: 34179092
PMC: 8226272.
DOI: 10.3389/fmolb.2021.687576.
Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy.
Chiang A, Baghdassarian H, Kellman B, Bao B, Sorrentino J, Liang C
J Biomed Sci. 2021; 28(1):50.
PMID: 34158025
PMC: 8218521.
DOI: 10.1186/s12929-021-00746-2.